Harris: open architecture ups research visibility

Share this article:
Most pharmaceutical firms use multiple marketing research suppliers, and many want suppliers to cull data for them. For those that want to do it on their own, a new service from Harris Interactive could be useful.

The integrated, Web-based system gives clients 24/7 access to all data collected regardless of interviewing mode.

“Why should a client need to wait to a get a top-line report, or even have to pick up the phone or send an e-mail to generate or retrieve information,” said Chris Kuever, Harris Interactive VP, technical sales.

With its marketing research platform GlobalSynch, they can log on and, depending on their access privileges, generate virtually any view of the data, from PowerPoint to PDF.

Being able to generate presentations whenever they're needed may help increase the visibility of research within client organizations, Kuever said, adding that the Harris research staff use the same system, creating a “collaborative environment.”

Harris says it's ideally suited to enterprise-level business intelligence and studies using multiple sample sources.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...